Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3GNRHRMPLPDE3APDE3BPDE4APDE4BPDE4CPDE4DPPARASLC5A2
The experimentally established mechanism targets of Dodecanoate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP3 | P05413 | 7/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | BBOX1 | O75936 | 2/20 | 0.47 |
| ▸ | CES2 | O00748 | 3/20 | 0.47 |
| ▸ | CES1 | P23141 | 3/20 | 0.47 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Myristic Acid SCHEMBL5317287 | 1.00 | FABP3 (0.53) | FABP3CA1BBOX1CES2CES1 | |
| Palmitic Acid SCHEMBL5319013 | 1.00 | FABP3 (0.53) | FABP3CA1BBOX1CES2CES1 | |
| Decanoic Acid SCHEMBL5318915 | 1.00 | FABP3 (0.53) | FABP3CA1BBOX1CES2CES1 | |
| Stearic Acid SCHEMBL3459527 | 1.00 | FABP3 (0.53) | FABP3CA1BBOX1CES2CES1 | |
| Decanoic Acid SCHEMBL580470 | 0.98 | FABP3 (0.55) | FABP3CA1BBOX1CES2CES1 | |
| Stearic Acid SCHEMBL840883 | 0.98 | FABP3 (0.55) | FABP3CA1BBOX1CES2CES1 | |
| Dodecanoate SCHEMBL19253062 | 0.98 | FABP3 (0.55) | FABP3CA1BBOX1CES2CES1 | |
| Palmitic Acid SCHEMBL10396224 | 0.98 | FABP3 (0.55) | FABP3CA1BBOX1CES2CES1 | |
| Myristic Acid SCHEMBL8588822 | 0.98 | FABP3 (0.55) | FABP3CA1BBOX1CES2CES1 | |
| Nonanoate SCHEMBL29370695 | 0.98 | FABP3 (0.55) | FABP3CA1BBOX1CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007079252-A2 | SUSTAINED RELEASE PHARMACEUTICAL COMPOSITIONS | AMPHASTAR PHARMACEUTICALS, INC. (US) | 2007-07-12 | — | — | WO | disclosed |
| US-20070154546-A1 | Sustained release pharmaceutical compositions | INTERNATIONAL MEDICATION SYSTEMS, LIMITED | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070154546-A1 | Sustained release pharmaceutical compositions | PLA2G2C, PLTP, F12 | FABP3 510/4885CA1 221/4885BBOX1 4512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.